UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 5, pp. 663 - 671
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Brain Neoplasms - diagnostic imaging | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Small Cell Lung Carcinoma - drug therapy | Small Cell Lung Carcinoma - secondary | Early Termination of Clinical Trials | Brain Neoplasms - secondary | Aged, 80 and over | Medical Futility | Adult | Female | Survival Rate | Cranial Irradiation - adverse effects | Brain Neoplasms - prevention & control | Small Cell Lung Carcinoma - prevention & control | Magnetic Resonance Imaging | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Intention to Treat Analysis | Small Cell Lung Carcinoma - diagnostic imaging | Watchful Waiting | Aged | Platinum Compounds - administration & dosage | Care and treatment | Chemotherapy | Lung cancer | Oncology, Experimental | Radiation | Clinical trials | Metastasis | Research | College teachers | Radiotherapy | Cancer | Analysis | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2017, Volume 390, Issue 10089, pp. 29 - 39
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Single-Blind Method | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Humans | Middle Aged | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Piperidines - blood | Brain Neoplasms - secondary | Pyridines - adverse effects | Carcinoma, Non-Small-Cell Lung - secondary | Neoplasm Grading | Antineoplastic Agents - adverse effects | Pyrazoles - blood | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Carbazoles - blood | Pyrazoles - adverse effects | Pyridines - therapeutic use | Carcinoma, Non-Small-Cell Lung - pathology | Carbazoles - adverse effects | Lung Neoplasms - enzymology | Kaplan-Meier Estimate | Receptor Protein-Tyrosine Kinases - metabolism | Protein Kinase Inhibitors - blood | Pyridines - blood | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Antineoplastic Agents - blood | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Respiratory agents | Care and treatment | Lymphomas | Lung cancer, Non-small cell | Product development | Pharmaceutical industry | Analysis | Toxicity | Funding | Lung cancer | Central nervous system | Metastasis | Kinases | Evidence-based medicine | Recruitment | Motivation | Audio frequencies | Safety | Toxic diseases | Drug dosages | Protein-tyrosine kinase | Effectiveness | Data processing | Group dynamics | Patients | Survival | Lymphoma | Chemotherapy | Inhibitors | Interactive systems | Death | Mutation | Cancer | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 2010, Volume 11, Issue 2, pp. 121 - 128
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Cisplatin - administration & dosage | Taxoids - administration & dosage | Female | Quinazolines - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Tyrosine | Medical colleges | Care and treatment | Molecular genetics | Clinical trials | Respiratory agents | Lung cancer, Non-small cell | Chemotherapy | Cancer patients | Epidermal growth factor | Product development | Gefitinib | Cancer | Index Medicus | Liver diseases | Epidermal growth factor receptors | Exons | Toxicity | Hypersensitivity | Lung cancer | Diarrhea | Fatigue | Gene deletion | Survival | Cisplatin | Recruitment | Hospitals | Point mutation | Myelosuppression | Pharmaceuticals | Thyroid
Journal Article
The lancet oncology, ISSN 1470-2045, 2013, Volume 14, Issue 7, pp. 590 - 598
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Carcinoma, Large Cell - drug therapy | Lung Neoplasms - drug therapy | Prognosis | Follow-Up Studies | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Immunoenzyme Techniques | Adenocarcinoma - metabolism | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Piperidines - pharmacokinetics | Adenocarcinoma - genetics | Carcinoma, Large Cell - genetics | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | Carcinoma, Large Cell - metabolism | Carcinoma, Non-Small-Cell Lung - genetics | Carcinoma, Non-Small-Cell Lung - metabolism | Receptor Protein-Tyrosine Kinases - metabolism | Adenocarcinoma - drug therapy | Maximum Tolerated Dose | Carcinoma, Squamous Cell - drug therapy | Receptor Protein-Tyrosine Kinases - genetics | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Gene Rearrangement | Carbazoles - pharmacokinetics | Aged | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Care and treatment | Oncology, Experimental | Research | College teachers | Lung cancer, Non-small cell | Drug approval | Cancer | Index Medicus
Journal Article
Respiratory investigation, ISSN 2212-5345, 2016, Volume 55, Issue 2, pp. 184 - 187
Internal Medicine | Pulmonary/Respiratory | Lung cancer | Brain metastasis | Stereotactic radiotherapy | Radiation necrosis | Bevacizumab | Necrosis - drug therapy | Brain - diagnostic imaging | Adenocarcinoma - pathology | Bevacizumab - therapeutic use | Humans | Middle Aged | Brain Neoplasms - pathology | Lung Neoplasms - pathology | Male | Necrosis - surgery | Radiosurgery - adverse effects | Adenocarcinoma - secondary | Necrosis - diagnostic imaging | Magnetic Resonance Imaging | Brain Neoplasms - secondary | Necrosis - etiology | Brain - pathology | Brain - surgery | Brain Neoplasms - radiotherapy | Adenocarcinoma - radiotherapy | Usage | Analysis | Radiosurgery | Metastasis | Drug therapy | Risk factors | Index Medicus
Journal Article
The Journal of thoracic and cardiovascular surgery, ISSN 0022-5223, 01/2021, Volume 161, Issue 1, pp. 281 - 290
Journal Article
Cancer science, ISSN 1347-9032, 03/2019, Volume 110, Issue 3, pp. 1012 - 1020
pembrolizumab | phase 1 | non–small‐cell lung cancer | immunotherapy | PD‐L1 | PD-L1 | non–small-cell lung cancer | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Antibodies, Monoclonal, Humanized - therapeutic use | Humans | Lung Neoplasms - metabolism | Carcinoma, Non-Small-Cell Lung - metabolism | Male | Antineoplastic Agents - therapeutic use | Disease-Free Survival | Asian Continental Ancestry Group | B7-H1 Antigen - metabolism | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Medical research | Care and treatment | Chemotherapy | Immunotherapy | Monoclonal antibodies | Medicine, Experimental | Lung cancer, Non-small cell | Cancer | Medical imaging | Cell survival | Toxicity | Mortality | Lung cancer | Non-small cell lung carcinoma | Cytotoxicity | Metastasis | Cancer therapies | Pembrolizumab | Pneumonitis | Platinum | Antitumor activity | Ligands | Death | Mutation | Apoptosis | Pharmaceuticals | Index Medicus | Original
Journal Article
Japanese journal of clinical oncology, ISSN 0368-2811, 01/2021, Volume 51, Issue 1, pp. 28 - 36
Journal Article
Lung cancer (Amsterdam, Netherlands), ISSN 0169-5002, 09/2017, Volume 111, pp. 190 - 194
non-small cell lung cancer | EGFR mutation-positive | progressive disease | TBLB | NSCLC | epidermal growth factor receptor | Eastern Cooperative Oncology Group | Cytology | formalin-fixed, paraffin-embedded | EGFR | EGFRm | trans-bronchial lung biopsy | TKI | FFPE | Biopsy | ECOG | performance status | tyrosine kinase inhibitor | Mutation | standard deviation | Epidermal growth factor receptor | Non-small cell lung cancer | Respiratory System | Oncology | Life Sciences & Biomedicine | Science & Technology | Lung Neoplasms - genetics | Receptor, Epidermal Growth Factor - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Exons | Humans | Middle Aged | Male | Mutation Rate | Carcinoma, Non-Small-Cell Lung - diagnosis | DNA Mutational Analysis - methods | Multicenter Studies as Topic | Neoplasm Grading | Alleles | Female | Aged | Lung Neoplasms - diagnosis | Neoplasm Staging | Amino Acid Substitution | Index Medicus
Journal Article
Pharmacology & therapeutics (Oxford), ISSN 0163-7258, 08/2003, Volume 99, Issue 2, pp. 149 - 165
receptors | 5-HT | Intracellular calcium concentration | Vagal afferent nerve activity | 5-HT release | Anticancer drug-induced emesis | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Intestinal Mucosa - metabolism | Humans | Intestinal Mucosa - secretion | Vagus Nerve - drug effects | Serotonin - urine | Neurons, Afferent - physiology | Intestinal Mucosa - drug effects | Vagus Nerve - physiopathology | Serotonin - blood | Vomiting - chemically induced | Antineoplastic Agents - adverse effects | Enterochromaffin Cells - secretion | Neurons, Afferent - pathology | Serotonin - secretion | Neurons, Afferent - metabolism | Vomiting - physiopathology | Vomiting - prevention & control | Index Medicus
Journal Article